Hengrui Pharma(SH:600276) Zhi Tong Cai Jing·2026-01-07 02:26Core Viewpoint - Heng Rui Medicine (600276) (01276) has seen its stock price increase by over 4%, currently trading at 77.8 HKD with a transaction volume of 103 million HKD, following the announcement of two innovative drugs receiving approval for clinical trials targeting PSMA-positive prostate cancer [1] Group 1: Drug Approvals - Heng Rui Medicine announced that its two self-developed innovative drugs, HRS-4357 injection and HRS-5041 tablets, have been approved by the National Medical Products Administration for clinical trials [1] - HRS-4357 is a Class 1 radioactive therapeutic drug, and this approval represents an expansion based on its previous single-agent clinical trials [1] - HRS-5041 is a novel androgen receptor protein degradation-targeting small molecule drug, designed to treat prostate cancer by degrading AR proteins, with potential to overcome resistance to existing therapies [1] Group 2: Market Context - The announcement highlights that there are currently no similar products approved for market release, both domestically and internationally [1]